Low serum stability of natriuretic peptides and insufficient guanylate cyclase activation lead to worsening heart failure and pulmonary hypertension.

Standard kinase inhibitors often fail to overcome immunosuppressive tumor microenvironments or metabolic drug interactions that limit therapeutic efficacy.

Dysregulated Ras-protein interactions drive uncontrolled cellular proliferation and therapeutic resistance in various hyperproliferative oncology disorders.

Aberrant kinase signaling drives uncontrolled cellular proliferation and chronic inflammation in cancers and autoimmune conditions.